You are here

Aisling Capital Closes Health Focused Venture Capital Fund, at $280M

Aisling Capital, a NYC-based late-stage life sciences investment firm that partners with companies to bring novel medical therapies to market, closed its newest fund, at $280m.

The new fund will allow Aisling Capital to continue to back clinical stage ventures in order improve global health by rapidly bringing breakthrough medical treatments to market.

Read Complete Article